88 related articles for article (PubMed ID: 2385609)
1. Phase I/II study of intravesical epirubicin in patients with carcinoma in situ of the bladder.
Kurth KH; Mross K; ten Kate F; Weissglas G; Carpentier PJ; Krueger CG; Blom J; Groen JM; van Caubergh RD; van Aubel O
Prog Clin Biol Res; 1990; 350():41-59. PubMed ID: 2385609
[No Abstract] [Full Text] [Related]
2. Epirubicin in treatment and recurrence prophylaxis of patients with superficial bladder cancer.
Burk K; Kurth KH; Newling D
Prog Clin Biol Res; 1989; 303():423-34. PubMed ID: 2780657
[No Abstract] [Full Text] [Related]
3. [Intravesical instillation of epirubicin hydrochloride in superficial bladder tumor--prophylactic and therapeutic instillation for carcinoma in situ].
Shichiri Y; Kanba T; Yoshida S; Arai Y
Hinyokika Kiyo; 1995 May; 41(5):359-64. PubMed ID: 7598036
[TBL] [Abstract][Full Text] [Related]
4. Phase 1/2 study of intravesical epirubicin in patients with carcinoma in situ of the bladder.
Kurth K; Vijgh WJ; ten Kate F; Bogdanowicz JF; Carpentier PJ; Van Reyswoud I
J Urol; 1991 Dec; 146(6):1508-12; discussion 1512-3. PubMed ID: 1942329
[TBL] [Abstract][Full Text] [Related]
5. Effect of intravesical instillation on performance of uCYT+ test.
Lodde M; Mian C; Negri G; Vittadello F; Comploj E; Palermo S; Staffler A; Brössner C; Pycha A
Urology; 2004 May; 63(5):878-81. PubMed ID: 15134970
[TBL] [Abstract][Full Text] [Related]
6. Re: Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group Phase III Trial (30906).
Mehraban D; Esfahani F
J Urol; 2005 Sep; 174(3):1151; author reply 1151. PubMed ID: 16094088
[No Abstract] [Full Text] [Related]
7. 2-micrometer continuous wave laser treatment for multiple non-muscle-invasive bladder cancer with intravesical instillation of epirubicin.
Liu H; Xue S; Ruan Y; Sun X; Han B; Xia S
Lasers Surg Med; 2011 Jan; 43(1):15-20. PubMed ID: 21254138
[TBL] [Abstract][Full Text] [Related]
8. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study.
Ali-el-Dein B; el-Baz M; Aly AN; Shamaa S; Ashamallah A
J Urol; 1997 Jul; 158(1):68-73; discussion 73-4. PubMed ID: 9186325
[TBL] [Abstract][Full Text] [Related]
9. Cytological surveillance of carcinoma in situ during and after intravesical chemotherapy.
Roth S; Rathert P
Prog Clin Biol Res; 1989; 303():523-4. PubMed ID: 2780660
[No Abstract] [Full Text] [Related]
10. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
[TBL] [Abstract][Full Text] [Related]
11. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
de Reijke TM; Kurth KH; Sylvester RJ; Hall RR; Brausi M; van de Beek K; Landsoght KE; Carpentier P;
J Urol; 2005 Feb; 173(2):405-9. PubMed ID: 15643181
[TBL] [Abstract][Full Text] [Related]
12. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC
Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy and safety of different dosages of intravesical epirubicin instillation for prevention of primary superficial bladder carcinoma from recurrence].
Wu ZB; Lin GB; Chen BJ; Wu ZM; Rong RM
Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):507-9. PubMed ID: 16188156
[TBL] [Abstract][Full Text] [Related]
14. [BCG versus photodynamic therapy (PDT) for nonmuscle invasive bladder cancer-a multicentre clinical phase III study].
Jocham D; von Wietersheim J; Pflüger H; Steiner H; Doehn C; Büttner H; Böhle A; Kausch I
Aktuelle Urol; 2009 Mar; 40(2):91-9. PubMed ID: 19214951
[TBL] [Abstract][Full Text] [Related]
15. Organ conservation in bladder cancer.
Newling DW
Prog Clin Biol Res; 1991; 370():127-30. PubMed ID: 1924441
[No Abstract] [Full Text] [Related]
16. [Transitional cell carcinoma in prostate after intravesical instillation of Bacillus Calmette-Guerin].
Ito Y; Nishiyama H; Higashi S; Kinoshita H; Ito N; Yamamoto S; Kamoto T; Ogawa O
Hinyokika Kiyo; 2004 May; 50(5):335-8. PubMed ID: 15237488
[TBL] [Abstract][Full Text] [Related]
17. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
18. Drug eruption due to intravesical instillations of both epirubicin and mitomycin C.
Okumura A; Oishi N; Kaji K; Imamura T; Fuse H
J Dermatol; 2009 Jul; 36(7):419-22. PubMed ID: 19583691
[TBL] [Abstract][Full Text] [Related]
19. [Results of clinical study with epirubicin hydrochloride injectable solution for superficial bladder cancer. IMI28 Injectable Solution Study Group for Superficial Bladder Cancer].
Kotake T; Koyanagi T; Akaza H; Shimazaki J; Ito H; Hosaka M; Okajima E; Saito Y; Miyanaga N; Kuroda M; Hirao Y
Gan To Kagaku Ryoho; 1998 Jul; 25(8):1189-95. PubMed ID: 9679582
[TBL] [Abstract][Full Text] [Related]
20. [Mitomycin C in the topical treatment of superficial neoplasms of the bladder].
Milani C; Bassi PF; Meneghini A; Giunta A; Tejerizo JC; dal Bianco M; Zattoni F; Garbeglio A
Arch Esp Urol; 1989 Oct; 42(8):761-7. PubMed ID: 2515812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
